Ymmunobio AG Signs Patent Purchase Agreement with LeukoCom GmbH
Ymmunobio AG has signed a patent purchase agreement with LeukoCom GmbH to expand its development of cancer therapies.
Ymmunobio AG, a biotech company specializing in the development of CEACAM antibodies as anti-cancer treatments, announced on April 7, 2022 that it has signed a purchase agreement with LeukoCom GmbH. The agreement will grant Ymmunobio AG ownership of the patents and intellectual property to several CEACAM antibodies.
Ymmunobio AG will have the rights to all future CEACAM-related patents developed or secured by LeukoCom GmbH. The company also has the rights to CEACAM1 antibodies YB-200, YB-300, YB-400, and one additional antibody targeting CEACAM8.
The company is focused on employing the immune system in the development of cancer therapies by developing a proprietary class of CEACAM antibodies to increase the efficiency of the immune system to fight cancer.
"We are excited to obtain the patent rights to the new immune-agonistic CEACAM antibodies,” said Dr. Katrin Rupalla, CEO of Ymmunobio AG, in a press release. “There are potential significant advantages for the treatment of solid tumors in leveraging both the physiological and pathophysiological roles of CEACAMs. This broader mechanism is a benefit as compared to other CEACAM antibodies and novel checkpoint inhibitors currently in development.”
Source: Ymmunobio AG
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
